4basebio (XTER:88Q) Debt-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

4basebio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. 4basebio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. 4basebio's annualized Revenue for the quarter that ended in Jun. 2023 was €0.55 Mil. 4basebio's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

4basebio Debt-to-Revenue Historical Data

The historical data trend for 4basebio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Debt-to-Revenue Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Revenue

12.83

3.72

5.20

12.51

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Revenue	Get a 7-Day Free Trial			-	5.53	-	14.48	-

Competitive Comparison of 4basebio's Debt-to-Revenue

For the Biotechnology subindustry, 4basebio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where 4basebio's Debt-to-Revenue falls into.

4basebio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

4basebio's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.477	+	3.375)	/	0.308
	=	12.51

4basebio's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.554
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.

4basebio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of 4basebio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines